Biosimilar Uptake on the Rise in Europe

January 10, 2023

A newly released report by IQVIA finds that the uptake of biosimilars is growing in 23 European countries. Spending on biologics grew in the past year, accounting for 35% of total drug spending. Biosimilars now directly compete with 18 original biologics in the region, with nearly 4 copycats per compound on average. However, this doesn’t mean that all patients are seeing the immediate benefits of said competition.

According to Skylar Jeremias, “Countries where patients pay for their biologic treatments out of pocket or with a co-pay, such as Poland, may find it difficult to afford their medications. Additionally, smaller manufacturers of biosimilars have recorded increased costs for packaging and distribution of medications and payers will face increased pressure to create savings and reduce the long-term impact that the pandemic had on health care systems.”

To read more, click here.

(Source: AJMC Biosimilars, January 10th, 2023)

Share This Story!